Automating the assessment of delirium severity in ICU patients
Harnessing the Power of Technology to Transform Delirium Severity Measurement in the ICU
This study is testing a new way to measure how severe delirium is in ICU patients over 50 by using bedside cameras and comparing it to traditional methods.
Quick facts
| Study type | Observational |
|---|---|
| Enrollment | 400 (estimated) |
| Ages | 50 Years and up |
| Sex | All |
| Sponsor | Mayo Clinic Academic / other |
| Locations | 1 site (Rochester, Minnesota) |
| Trial ID | NCT06172491 on ClinicalTrials.gov |
What this trial studies
This observational study aims to develop a passive digital marker (PDM) to assess delirium severity in ICU patients over 50 years old. Participants will be monitored using bedside cameras for 24 hours a day, with study staff conducting assessments four times daily to compare the PDM's performance against established delirium severity tools. The study will evaluate the reliability of a trained convolutional neural network in measuring delirium severity and its acceptability among ICU staff and patients. The goal is to enhance the accuracy and efficiency of delirium assessments in critical care settings.
Who should consider this trial
Good fit: Ideal candidates are ICU patients over 50 years old who are expected to stay in the ICU for more than 24 hours and are not admitted for substance-related issues.
Not a fit: Patients admitted for acute alcohol intoxication, drug overdose, or those with acute neuronal injury may not benefit from this study.
Why it matters
Potential benefit: If successful, this study could lead to more accurate and timely assessments of delirium severity, improving patient care in the ICU.
How similar studies have performed: While the use of digital markers and AI in healthcare is an emerging field, this specific approach to delirium assessment is novel and has not been extensively tested in prior studies.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: • Age \>50; * Estimated length of stay \>24 hours in ICU; and * Are not admitted for acute alcohol intoxication, drug (prescribed or illicit) overdose or withdrawal. Exclusion Criteria: * Admitted for acute alcohol intoxication, drug (prescribed or illicit) overdose or withdrawal. * Admitted for acute neuronal injury * Unable to communicate with research team due to sensory deficits (aphasic, blind, deaf) or language (does not speak English)
Where this trial is running
Rochester, Minnesota
- Mayo Clinic — Rochester, Minnesota, United States (Recruiting)
Study contacts
- Study coordinator: Heidi Lindroth, PH.D. R.N.
- Email: lindroth.heidi@mayo.edu
- Phone: 507-284-3662
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.